|
Business
Zacks Bull and Bear of the Day Highlights: IBM Corporation, United Therapeutics, Greatbatch, Genuine Parts and School Specialty
© Business Wire 2008
2008-08-27 14:31:02 - - Zacks Equity Research highlights IBM Corporation (NYSE: IBM) as the Bull of the Day and United Therapeutics (Nasdaq: UTHR) as the Bear of the Day. In addition, Zacks Equity Research provides analysis on Greatbatch, Inc. (NYSE: GB), Genuine Parts Co. (NYSE: GPC) and School Specialty (Nasdaq: SCHS).
Full analysis of all these stocks is available at
|
|
| title="http://at.zacks.com/?id=2676" rel="nofollow" target="_blank">at.zacks.com/?id=2676.
Here is a synopsis of all five stocks:
Bull of the Day: IBM Corporation (NYSE: IBM)
With over half of its revenue (58%) coming from outside the United States, IBM Corporation has been insulated from recent weakness in the U.S. economy than many of its peers. Although this trend may be ending as the U.S. economy picks up strength relative to Europe, IBM should continue to benefit from its focus on faster-growing markets through a series of acquisitions and divestiture of mature businesses.
Moreover, its position in emerging markets should continue to help drive growth. We maintain our Buy rating on IBM shares and a target price of $140.00.
Bear of the Day: United Therapeutics (Nasdaq: UTHR)
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of therapeutic products for patients with chronic and life-threatening diseases. It offers products primarily in three therapeutic areas, including cardiovascular, cancer, and infectious diseases.
Although we believe current business fundamentals are solid, we are seeing several potential hiccups coming in the next year. And, with the stock up 65% over the past twelve months and currently trading at 50x our 2008 EPS estimate, we believe investors are pricing the stock for near flawless execution. Expectations are high, and any slip-up, even minor, may cause a sell-off in the shares. As a result, we are initiating with a Sell rating and an $82 price target.
Latest Posts on the Zacks Analyst Blog:
Greatbatch, Inc. (NYSE: GB)
Greatbatch is a leading producer and supplier of batteries, capacitors, and components used in implantable medical devices through its Implantable Medical Components (IMC) business.
The company reported second quarter top-line above expectations primarily due to acquisitions and strong end-market growth. However, EPS exceeded our expectations by a penny on lower R&D spending. The management provides adjusted 2008 EPS guidance of $1.20-$1.50. Our 2008 EPS estimates increase on positive news surrounding new products and promising innovations, and diversification beyond the CRM original equipment manufacturers, now less than 50% of Q208 sales.
Genuine Parts Co. (NYSE: GPC)
Genuine Parts has undertaken various initiatives such as product line expansion, penetration into new markets and acquisitions to boost sales and earnings. Genuine Parts has been diversifying its revenue base to reduce excessive dependence on the automotive replacement market.
The company's electronic and industrial parts businesses are showing impressive performance and it has a strong balance sheet. However, our optimism is dampened by the sluggish automotive and office products industries in the U.S. Considering these factors, we maintain our Hold recommendation with a target price of $43.
School Specialty (Nasdaq: SCHS)
In the first quarter, School Specialty, Inc.'s earnings per share were $0.16 below the consensus estimate and $0.15 below our estimate. In addition, the management updated its guidance for fiscal 2009. The company continues to expect revenue of $1.08-$1.11 billion, but it lowered its EPS guidance from $2.27-$2.43 to $2.23-$2.39 to account for a $0.04/share cost to closing a distribution center in the second quarter.
We are slightly reducing our 2009 EPS from $2.30 to $2.28 but leaving our fiscal 2010 EPS estimate at $2.45. School Specialty's industry-leading market position and cost-cutting efforts are offset by growing competitive pressures and limited organic growth prospects. We maintain our Hold rating on the stock.
Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: at.zacks.com/?id=2649.
About the Bull and Bear of the Day
Every day, the analysts at Zacks Equity Research select two stocks that are likely to outperform (Bull) or underperform (Bear) the markets over the next 3-6 months.
About the Analyst Blog
Updated throughout every trading day, the Analyst Blog provides analysis from Zacks Equity Research about the latest news and events impacting stocks and the financial markets.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today by visiting at.zacks.com/?id=2677.
About Zacks
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at at.zacks.com/?id=4582.
Visit www.zacks.com/performance for information about the performance numbers displayed in this press release.
Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.
Zacks.com
Mark Vickery
312-265-9380
Visit: www.zacks.com
|
| Disclaimer:
(c) 2007 Business Wire. All of the news releases contained herein are protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Business Wire's members, who warrant that they are solely responsible for the content, accuracy and originality of the information contained therein. All reproduction, other than for an individual user's personal reference, is prohibited without prior written permission.
|
 |
|
